Advertisement
ADPT or ISRG or NTRA
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Intuitive Surgical (ISRG) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- ADPT, ISRG, and NTRA operate in distinct healthcare niches—immune sequencing, robotic surgery, and cell-free DNA diagnostics—exposing them to different growth drivers and risk profiles.
- Recent market activity shows ISRG experiencing notable pressure with year-to-date declines amid broader sector sentiment, while NTRA has shown resilience with periodic highs supported by test adoption.
- ADPT remains focused on partnerships and clinical validation in oncology and immunology, with performance tied to biotech funding cycles and data readouts.
- Valuation sensitivity varies, with growth-oriented names like NTRA and ISRG reacting more to earnings beats or procedure volumes than ADPT's earlier-stage metrics.
- Sector exposure centers on healthcare innovation, where regulatory approvals, reimbursement, and technological adoption influence relative momentum across the three.
- Market sentiment reflects a mix of long-term tailwinds in precision medicine offset by near-term macroeconomic and operational considerations.
Introduction
Traders and investors often compare stocks within the healthcare sector to assess relative positioning amid evolving technological and clinical landscapes. ADPT, ISRG, and NTRA represent complementary yet distinct approaches to precision health—spanning immune profiling, minimally invasive surgery, and advanced genetic testing. This comparison appeals to those evaluating growth opportunities in biotechnology and medical technology, particularly individuals seeking to understand how business models, recent momentum, and external factors differentiate these names in the current environment.
ADPT Overview and Recent Performance
Adaptive Biotechnologies Corp. develops immune system mapping technologies and minimal residual disease (MRD) testing for oncology and immunology applications. In recent weeks, the stock has reflected broader biotech sector dynamics, with performance influenced by clinical trial updates and partnership announcements. Sentiment has been shaped by ongoing validation of its clonoSEQ assay and collaborations aimed at expanding therapeutic applications. Market activity shows measured trading volumes, consistent with a company navigating development-stage milestones rather than large-scale commercialization.
ISRG Overview and Recent Performance
Intuitive Surgical, Inc. pioneers robotic-assisted surgical systems, primarily the da Vinci platform, serving hospitals worldwide. Recent market activity has featured downward pressure, with the stock declining notably year-to-date amid concerns over procedure volumes and a Class II recall of certain components. Second-quarter results exceeded revenue expectations, yet shares reacted to softer sentiment around overall surgical trends. Performance in recent weeks underscores sensitivity to macroeconomic factors affecting hospital capital spending and utilization rates.
NTRA Overview and Recent Performance
Natera, Inc. specializes in cell-free DNA (cfDNA) testing for oncology, women's health, and organ health, with key offerings including Signatera for MRD monitoring. In recent weeks, the stock has demonstrated relative strength, periodically reaching new highs supported by analyst target increases and expanded partnerships. Performance reflects growing adoption of its molecular diagnostics, though it remains subject to reimbursement dynamics and competitive pressures in the precision medicine space.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Available bots span a wide range of performance metrics, with historical win rates often falling between 55% and 75% depending on strategy, alongside varying drawdowns and trade frequencies. Each bot employs distinct styles, timeframes, and ticker sets, allowing users to match approaches to individual risk tolerances. Review the full selection on the Trending AI Robots page for detailed statistics.
Head-to-Head Comparison
Business models differ markedly: ADPT emphasizes research-oriented immune sequencing with revenue tied to collaborations, while ISRG generates recurring revenue from system sales and instruments, and NTRA focuses on high-volume diagnostic testing with reimbursement-driven economics. Growth drivers include clinical adoption for NTRA, procedural volume recovery for ISRG, and data-driven partnerships for ADPT. Recent momentum has favored NTRA relative to ISRG's drawdown, with ADPT showing steadier but lower-visibility movement. Risk factors encompass regulatory and reimbursement hurdles for all three, amplified by sector valuation sensitivity to interest rates and healthcare spending. Market sentiment remains constructive on long-term innovation yet cautious on near-term execution across the group.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative stability amid recent volatility, Tickeron’s AI would currently assign a probabilistic edge to NTRA for its demonstrated resilience and catalyst alignment in diagnostics adoption. ISRG presents a potential recovery setup if procedure trends stabilize, while ADPT offers longer-term optionality dependent on clinical milestones. This assessment draws from pattern recognition across performance data and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s), and NTRA’s FA Score reflects 1 green FA rating(s).
- ADPT’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 6 bullish TA indicator(s), and NTRA’s TA Score reflects 3 bullish TA indicator(s).
- ADPT’s TA Score: 5 bullish, 4 bearish.
- ISRG’s TA Score: 6 bullish, 3 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +10.46% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +7.21% , and NTRA (@Medical Specialties) price fluctuated +20.29% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.28%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +2.65%.
Reported Earning Dates
ADPT is expected to report earnings on Nov 05, 2026.
ISRG is expected to report earnings on Oct 20, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+4.28% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ADPT | ISRG | NTRA | |
| Capitalization | 3.97B | 134B | 46.4B |
| EBITDA | -20.94M | 4.25B | -227.7M |
| Gain YTD | 53.510 | -33.115 | 40.600 |
| P/E Ratio | N/A | 43.44 | N/A |
| Revenue | 295M | 11B | 2.5B |
| Total Cash | 218M | 5.22B | 1.09B |
| Total Debt | 77.6M | 87M | 240M |
ADPT | ISRG | NTRA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 71 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | 22 | |
SMR RATING 1..100 | 98 | 51 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | 64 | 35 | |
P/E GROWTH RATING 1..100 | 100 | 86 | 100 | |
SEASONALITY SCORE 1..100 | 35 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (47) in the Hospital Or Nursing Management industry is in the same range as NTRA (49) in the Biotechnology industry, and is in the same range as ISRG (71) in the Medical Specialties industry. This means that ADPT's stock grew similarly to NTRA’s and similarly to ISRG’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for ISRG (86) in the Medical Specialties industry, and is significantly better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that NTRA's stock grew somewhat faster than ISRG’s and significantly faster than ADPT’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NTRA (96) in the Biotechnology industry, and is somewhat better than the same rating for ADPT (98) in the Hospital Or Nursing Management industry. This means that ISRG's stock grew somewhat faster than NTRA’s and somewhat faster than ADPT’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ADPT (35) in the Hospital Or Nursing Management industry, and is in the same range as ISRG (64) in the Medical Specialties industry. This means that NTRA's stock grew similarly to ADPT’s and similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (86) in the Medical Specialties industry is in the same range as NTRA (100) in the Biotechnology industry, and is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that ISRG's stock grew similarly to NTRA’s and similarly to ADPT’s over the last 12 months.
| ADPT | ISRG | NTRA | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 79% | 3 days ago 60% | 3 days ago 75% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 59% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 71% | 3 days ago 76% |
| MACD ODDS (%) | 3 days ago 85% | 3 days ago 63% | 3 days ago 73% |
| TrendWeek ODDS (%) | 3 days ago 83% | 3 days ago 63% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 70% | 3 days ago 81% |
| Advances ODDS (%) | 5 days ago 83% | 7 days ago 66% | 6 days ago 80% |
| Declines ODDS (%) | 28 days ago 86% | 11 days ago 61% | 4 days ago 77% |
| BollingerBands ODDS (%) | 3 days ago 84% | 3 days ago 73% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 86% | 3 days ago 73% | 3 days ago 83% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ISHP | 36.87 | 0.56 | +1.54% |
| First Trust S-Network Glb E-Com ETF | |||
| NDMO | 10.02 | 0.09 | +0.91% |
| Nuveen Dynamic Municipal Opportunities Fund | |||
| SPMB | 22.03 | 0.07 | +0.32% |
| State Street SPDR Port Mortg Bckd Bd ETF | |||
| MYCJ | 24.49 | 0.04 | +0.18% |
| State Street® My2030 Corporate Bond ETF | |||
| TOLZ | 58.96 | -0.15 | -0.26% |
| ProShares DJ Brookfield Global Infras | |||
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +1.36% | ||
| BSX - ISRG | 73% Closely correlated | +0.02% | ||
| SYK - ISRG | 64% Loosely correlated | +0.47% | ||
| NTRA - ISRG | 54% Loosely correlated | +21.37% | ||
| GKOS - ISRG | 51% Loosely correlated | +5.28% | ||
| PODD - ISRG | 49% Loosely correlated | +1.34% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +21.37% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.36% | ||
| GH - NTRA | 50% Loosely correlated | +6.92% | ||
| ADPT - NTRA | 49% Loosely correlated | +5.64% | ||
| MTD - NTRA | 47% Loosely correlated | +0.58% | ||
| GKOS - NTRA | 47% Loosely correlated | +5.28% | ||
More | ||||